Duopharma Biotech Bhd (XKLS:7148) Cyclically Adjusted Revenue per Share: RM0.83 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKLS:7148 Duopharma Biotech Bhd XKLS:7148
82 GF Score
Price RM1.22
GF Value RM1.53
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share?

Duopharma Biotech Bhd XKLS:7148 82 Cyclically Adjusted Revenue per Share is RM0.83 as of Mar. 2026. GuruFocus rates XKLS:7148 with a GF Score™ of 82/100 and a GF Value™ of RM1.53 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Duopharma Biotech Bhd's adjusted revenue per share for the three months ended in Mar. 2026 was RM0.258. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is RM0.83 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Duopharma Biotech Bhd's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Duopharma Biotech Bhd was 11.50% per year. The lowest was 8.30% per year. And the median was 10.40% per year.

As of today (2026-07-18), Duopharma Biotech Bhd's current stock price is RM1.22. Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was RM0.83. Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio of today is 1.47.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Duopharma Biotech Bhd was 6.28. The lowest was 1.45. And the median was 1.94.


Duopharma Biotech Bhd  (XKLS:7148) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.22/0.83
=1.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Duopharma Biotech Bhd was 6.28. The lowest was 1.45. And the median was 1.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share Related Terms


Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share Chart

Duopharma Biotech Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.63 0.68 0.74 0.80

Duopharma Biotech Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.78 0.79 0.80 0.83

XKLS:7148 vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Duopharma Biotech Bhd Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's Cyclically Adjusted PS Ratio falls into.


XKLS:7148
82GF Score
Duopharma Biotech Bhd XKLS:7148
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duopharma Biotech Bhd Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Duopharma Biotech Bhd's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.258/330.2130*330.2130
=0.258

Current CPI (Mar. 2026) = 330.2130.

Duopharma Biotech Bhd Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.091 241.018 0.125
201609 0.092 241.428 0.126
201612 0.085 241.432 0.116
201703 0.139 243.801 0.188
201706 0.315 244.955 0.425
201709 0.133 246.819 0.178
201712 0.129 246.524 0.173
201803 0.154 249.554 0.204
201806 0.143 251.989 0.187
201809 0.143 252.439 0.187
201812 0.131 251.233 0.172
201903 0.171 254.202 0.222
201906 0.162 256.143 0.209
201909 0.159 256.759 0.204
201912 0.151 256.974 0.194
202003 0.174 258.115 0.223
202006 0.157 257.797 0.201
202009 0.144 260.280 0.183
202012 0.142 260.474 0.180
202103 0.180 264.877 0.224
202106 0.165 271.696 0.201
202109 0.182 274.310 0.219
202112 0.163 278.802 0.193
202203 0.195 287.504 0.224
202206 0.192 296.311 0.214
202209 0.186 296.808 0.207
202212 0.160 296.797 0.178
202303 0.211 301.836 0.231
202306 0.175 305.109 0.189
202309 0.175 307.789 0.188
202312 0.173 306.746 0.186
202403 0.201 312.332 0.213
202406 0.226 314.175 0.238
202409 0.217 315.301 0.227
202412 0.202 315.605 0.211
202503 0.273 319.799 0.282
202506 0.231 322.561 0.236
202509 0.231 324.800 0.235
202512 0.234 324.054 0.238
202603 0.258 330.213 0.258

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of RM0.83 mean?
Duopharma Biotech Bhd (XKLS:7148) has a Cyclically Adjusted Revenue per Share of RM0.83 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share too high?
Duopharma Biotech Bhd's current Cyclically Adjusted Revenue per Share is RM0.83. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Duopharma Biotech Bhd's Cyclically Adjusted Revenue per Share of RM0.83 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current Cyclically Adjusted Revenue per Share is RM0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.53, compared to a current price of RM1.22 — trading 20.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is RM0.83. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Cyclically Adjusted Revenue per Share is RM0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?

Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued. The current stock price of RM1.22 is trading 20.3% below its estimated GF Value™ of RM1.53. GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:7148:

  • Cyclically Adjusted Revenue per Share: RM0.83
  • GF Value™: RM1.53 vs. price of RM1.22 (20.3% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Duopharma Biotech Bhd Business Description

Address Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score

Get the complete analysis for XKLS:7148

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.22
Price
RM1.53
GF Value